Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program
News Dec 30, 2009
Affomix Corporation has announced that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer.
Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics. The company's portfolio of oncology products is at various stages in development, from assay development to advanced clinical trials.
“After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets”
Under the terms of the agreement Affomix will generate antibodies against several proprietary targets selected by Kalgene. Affomix will utilize its Y2HExpress™ technology for the selection of single-chain antibodies with substantially increased throughput, and specificity, over conventional Y2H and alternative antibody selection methodologies.
Financial terms of the service agreement were not disclosed, nor were the financial milestones related to diagnostic and therapeutic applications.
“After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets”, said Dr. T. Nathan Yoganathan, President and CEO of Kalgene Pharmaceuticals Inc. “Y2HExpress™ has the ability to select antibodies at an unprecedented level of specificity, combined with very favorable financial advantages,” Yoganathan continued.
“The application of Affomix technology will accelerate our product development schedule”, said Robert Davidson, Director of Science and Technology for Kalgene.
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Pap Test Fluids Used to Test for Endometrial & Ovarian CancersNews
Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.
UroSEEK Enables Noninvasive Detection of Bladder CancerNews
Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.READ MORE